NCT04324151 Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
| NCT ID | NCT04324151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hunan Province Tumor Hospital |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2020-03-24 |
| Primary Completion | 2024-12-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2020-03-24 with a primary completion date of 2024-12-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria: * ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Potentially Resectable NSCLC * Treatment Plan is Crizotinb or Standard Chemotherapy Exclusion Criteria: * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Contact & Investigator
Yongchang Zhang
PRINCIPAL INVESTIGATOR
Hunan Cancer Hospital
Frequently Asked Questions
Who can join the NCT04324151 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04324151 currently recruiting?
Yes, NCT04324151 is actively recruiting participants. Contact the research team at zhangyongchang@csu.edu.cn for enrollment information.
Where is the NCT04324151 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT04324151 clinical trial?
NCT04324151 is sponsored by Hunan Province Tumor Hospital. The principal investigator is Yongchang Zhang at Hunan Cancer Hospital. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.